#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neuronal ceroid lipofuscinosis Intracranial germ cell tumour Pouchitis Cognitive disorder Brain stem glioma Turner's syndrome Lymphangiosarcoma B-cell lymphoma recurrent Non-small cell lung cancer metastatic Infective uveitis Methylmalonic acidaemia Cholangitis sclerosing Fibrosarcoma Cutaneous T-cell lymphoma stage II Thymic carcinoma More trials…

    Learn about Rare Diseases

    Hereditary ataxia – Trials in Disease Glomerulonephritis membranous – Treatment Friedreich’s ataxia – Treatment Splenic marginal zone lymphoma – Treatment Primary immunodeficiency syndrome Immunodeficiency congenital – Life with Disease Von Willebrand’s disease – Life with Disease Mast cell activation syndrome – Life with Disease Richter’s syndrome – Life with Disease Rhabdomyosarcoma recurrent – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ucp4 Diphenhydramine Hydrochloride Resatorvid Mk-4830 Sabestomig Alirocumab Islatravir Roginolisib Guanabenz Acetate Pbf-999 Magnesium Citrate Abc-31-116 ANX007 Dotatate Dapirolizumab Pegol HSP-CAR19M Indocyanine Green ANERATRIGINE MESILATE Baxdrostat Inupadenant Hydrochloride More therapies…

    Learn about Your Condition

    Choroidal dystrophy Friedreich's ataxia Fabry's disease Gaucher's disease type I Agitation Hereditary angioedema Urinary incontinence Precocious puberty Gaucher's disease type III Pleomorphic leiomyosarcoma Adenomyosis Pelvic venous thrombosis Shprintzen-Goldberg syndrome Post procedural complication Retinal neovascularisation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie…

Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie

Uap Jfqvldemdqoy Nu 7fc Oyphzqil 1rdohky Pxnxdd

Want to learn more about this study or check if you can participate? Contact us.

  • Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Durvalumab
    • Infliximab
    • Mycophenolate Mofetil
    Belgium Bulgaria Czechia France Germany Greece +5

  • Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

    Recruiting

    3 1 1
    Investigated Drugs:
    • Mk-1084
    • Pembrolizumab
    Austria Bulgaria France Germany Greece Italy +4

  • Safety and Tolerability of Alisertib Sodium and Paclitaxel in Patients with Small Cell Lung Cancer (Phase 2 Study)

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Alisertib Sodium
    • Paclitaxel
    France Poland Spain

  • A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

    Recruiting

    3 1
    Investigated Diseases:
    • Non-small cell lung cancer stage I
    Investigated Drugs:
    • Mrna-4157
    • Pembrolizumab
    France Germany Greece Hungary Italy The Netherlands +2

  • Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Durvalumab
    • Mk-1084
    France Germany Greece Italy The Netherlands Poland +1

  • A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Atezolizumab
    • Carboplatin
    • Etoposide
    Austria Belgium Bulgaria Czechia Estonia Finland +14

  • A study to investigate the safety and effects of ceralasertib, tremelimumab, and durvalumab in adults with various solid tumors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Small cell lung cancer
    • Hepatocellular carcinoma
    • Non-small cell lung cancer
    Investigated Drugs:
    • Hyaluronidase (Human Recombinant)
    • Durvalumab
    • Infliximab
    Poland

  • A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Datopotamab Deruxtecan
    • Docetaxel
    Austria Belgium France Germany Hungary Italy +2

  • Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Small cell lung cancer extensive stage
    • Small cell lung cancer
    • Small cell lung cancer metastatic
    Investigated Drugs:
    • BNT327
    • Atezolizumab
    • Carboplatin
    France Germany Italy The Netherlands Poland Romania +1

  • Study of STK-012 Alone and Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Pembrolizumab
    • Pemetrexed
    Ireland Italy Poland Spain
1 2 3 … 8
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!